Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Ivanidze J, Roytman M, Lin E, Magge RS, Pisapia DJ, Liechty B, et al. Gallium-68 DOTATATE PET in the Evaluation of Intracranial Meningiomas. J Neuroimaging. 2019;29(5):650-656.

Weinberg OK, Hasserjian RP, Baraban E, Ok CY, Geyer JT, Philip JK, et al. Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Mod Pathol. 2019;32(9):1373-1385.

Wallach AI, Magro CM, Franks AG, Shapiro L, Kister I. Protean Neurologic Manifestations of Two Rare Dermatologic Disorders: Sweet Disease and Localized Craniofacial Scleroderma. Curr Neurol Neurosci Rep. 2019;19(3):11.

Mueller FB, Yang H, Lubetzky M, Verma A, Lee JR, Dadhania DM, et al. Landscape of innate immune system transcriptome and acute T cell-mediated rejection of human kidney allografts. JCI Insight. 2019;4(13).

Ouseph MM, Krigman H, He M. - An Uncommon but Noteworthy Cause of Intrauterine Fetal Demise and Acute Necrotizing Funisitis. Fetal Pediatr Pathol. 2019;38(4):352-358.

Chavda KD, Westblade LF, Satlin MJ, Hemmert AC, Castanheira M, Jenkins SG, et al. First Report of - and -Coharboring Species Isolated from a Pediatric Patient. mSphere. 2019;4(5).

Qin H, Dong Z, Wang X, Cheng WA, Wen F, Xue W, et al. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Sci Transl Med. 2019;11(511).

Wen N, Guo B, Zheng H, Xu L, Liang H, Wang Q, et al. Bromodomain inhibitor jq1 induces cell cycle arrest and apoptosis of glioma stem cells through the VEGF/PI3K/AKT signaling pathway. Int J Oncol. 2019;55(4):879-895.

Kuchay S, Wang H, Marzio A, Jain K, Homer H, Fehrenbacher N, et al. GGTase3 is a newly identified geranylgeranyltransferase targeting a ubiquitin ligase. Nat Struct Mol Biol. 2019;26(7):628-636.

Schwartz GW, Manning B, Zhou Y, Velu P, Bigdeli A, Astles R, et al. Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors. Clin Cancer Res. 2019;25(2):573-583.